Showing results (1-10 of 16) with videos related to
Sort By:
Pageof 2
CNS Spectrums|December 17, 2013
How to switch to agomelatine after an unsuccessful try with paroxetine or venlafaxineMichel Lejoyeux, Sophie Matharan, Christian de BodinatJournal of Clinical Psychopharmacology|September 17, 2008
Efficacy of agomelatine in generalized anxiety disorder: a randomized, double-blind, placebo-controlled studyDan J Stein, Antti A Ahokas, Christian de BodinatMedecine Sciences : M/S|October 4, 2005
[Development of a new antidepressant : agomelatine]Elisabeth Mocaër, Bruno Delalleau, Pierre-Alain Boyer, et al.The Journal of Nervous and Mental Disease|June 16, 2009
The DSM-IV-based Generalized Anxiety Disorder Severity Scale: preliminary validation using data from a trial of agomelatine versus placeboDan J Stein, Dylan Fincham, Soraya Seedat, et al.International Clinical Psychopharmacology|November 16, 2012
Is it time to shift to better characterization of patients in trials assessing novel antidepressants? An example of two relapse prevention studies with agomelatineGuy M Goodwin, Patrice Boyer, Robin Emsley, et al.European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|December 29, 2015
Sustained efficacy of agomelatine 10 mg, 25 mg, and 25-50 mg on depressive symptoms and functional outcomes in patients with major depressive disorder. A placebo-controlled study over 6 monthsSidney H Kennedy, Alla Avedisova, Carole Belaïdi, et al.European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|February 18, 2014
A placebo-controlled study of three agomelatine dose regimens (10 mg, 25 mg, 25-50 mg) in patients with major depressive disorderSidney H Kennedy, Alla Avedisova, Natalia Giménez-Montesinos, et al.International Clinical Psychopharmacology|April 7, 2017
Antidepressant effect in older depressed patients: the lessons of two agomelatine trialsGuy M Goodwin, Pierre Thomas, Reinhard Heun, et al.Nature Reviews. Drug Discovery|June 26, 2010
Agomelatine, the first melatonergic antidepressant: discovery, characterization and developmentChristian de Bodinat, Béatrice Guardiola-Lemaitre, Elisabeth Mocaër, et al.Journal of Affective Disorders|June 8, 2018
Effect of agomelatine 25-50 mg on functional outcomes in patients with major depressive disorderSidney H Kennedy, Reinhard Heun, Alla Avedisova, et al.Pageof 2